Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · IEX Real-Time Price · USD
1.210
+0.040 (3.42%)
Jul 22, 2024, 10:30 AM EDT - Market open
Adaptimmune Therapeutics Employees
Adaptimmune Therapeutics had 449 employees as of December 31, 2023. The number of employees decreased by 85 or -15.92% compared to the previous year.
Employees
449
Change (1Y)
-85
Growth (1Y)
-15.92%
Revenue / Employee
$40,886
Profits / Employee
-$363,942
Market Cap
301.23M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SOPHiA GENETICS | 430 |
Poseida Therapeutics | 330 |
Alimera Sciences | 159 |
Enanta Pharmaceuticals | 145 |
Atea Pharmaceuticals | 75 |
Jasper Therapeutics | 45 |
Opthea | 24 |
ADAP News
- 4 weeks ago - ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company - Benzinga
- 6 weeks ago - Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise - Newsfile Corp
- 7 weeks ago - Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications - GlobeNewsWire
- 7 weeks ago - Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications - Newsfile Corp
- 2 months ago - Adaptimmune Reports Q1 2024 Financial and Business Updates - Newsfile Corp
- 2 months ago - Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital - Newsfile Corp
- 2 months ago - Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 - Newsfile Corp
- 3 months ago - Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated - Newsfile Corp